Comparative Guide
Restructuring & Insolvency
Switzerland
Tanja Luginbühl & Andreas Daniel Gschwend
Offering advice on the full spectrum of related matters, Lenz & Staehelin caters to clients across a broad range of sectors including biotech, pharmaceuticals, medical devices and healthcare providers. Key team members include dispute resolution expert Xavier Favre-Bulle, Andreas Rötheli and Guy Vermeil, who both handle transactional matters, and Thierry Calame, who specialises in IP issues. Stephan Erni’s diverse practice encompasses corporate and commercial issues, acquisitions and regulatory issues related to the launch of medical products in Switzerland. Harold Frey represents clients in international arbitrations and litigation proceedings before the Swiss courts.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- ‘Provides quick answers and insights from multiple perspectives we may not have considered.’
- 'The team was exceptionally precise and meticulous in their work. Their attention to detail was evident throughout the entire process, and they consistently met deadlines, proving to be extremely punctual.'
- 'What was particularly impressive was their ability to handle tasks outside their normal scope, demonstrating great flexibility and a strong grasp of complex dynamics. They adapted seamlessly to our needs as clients.'
- ‘The team is very knowledgeable. They know the Swiss patent system inside out.’
- 'Thierry Calame offers great advocacy. He remains calm and is decisive in high pressure situations.'
- ‘Professional and very reactive. We rely on them for high-stakes contracts, in particular start-ups creations.’
Key clients
- Abbott Laboratories
- Acino
- Alcon
- Alpha Health Group
- Altitude Management
- Asceneuron
- Bain Capital Private Equity
- Cinven
- Chord Therapeutics
- dacadoo
- Ferring
- Gyrus Capital
Work highlights
Represented MSD before the Federal Patent Court in an SPC infringement case.
Represented Merck in trade mark infringement litigation concerning the use of the sign "Merck" as part of domain names.
Represented a client in a patent invalidity claim against Janssen's patent protecting its blockbuster drug, Stelara.
Practice head
Xavier Favre-Bulle; Andreas Rotheli; Guy Vermeil; Thierry Calame; Stephan Erni; Harold Frey